SCM
IMCR icon

Soleus Capital Management’s Immunocore IMCR Stock Holding History

Soleus Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,400
Closed -$983K – 103
2023
Q2 		$983K Buy
+16,400
New +$936K 0.11% 85

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Soleus Capital Management's IMCR Position: Q3 2023 in Review

Soleus Capital Management sold out of Immunocore (IMCR) in Q3 2023, closing a stake of 16,400 shares — an estimated $983K sold.

Soleus Capital Management first reported a position in IMCR in Q2 2023 and held it in 1 quarter. The position peaked at $983K in Q2 2023. 125 funds tracked by Wall St. Rank hold IMCR as of Q3 2023.

  • Soleus Capital Management reported no remaining Immunocore position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 16,400 Immunocore shares in Q3 2023, an estimated $983K.
  • Soleus Capital Management first reported a position in Immunocore in Q2 2023 and held it in 1 quarter.
  • Soleus Capital Management's Immunocore position peaked at $983K in Q2 2023.
  • 125 funds tracked by Wall St. Rank held Immunocore as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.